A Multi-Centre Randomized Study Comparing Two Standard of Care Chemotherapy Regimens for Lower-Risk HER2-Positive Breast Cancer

Background: Neither paclitaxel plus trastuzumab (P-H) nor docetaxel-cyclophosphamide plus trastuzumab (TC-H) have been prospectively compared in HER2-positive early-stage breast cancer (EBC). A randomized trial was performed to assess the feasibility of a larger study. Methods: Lower-risk HER2-posit...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernandes, Ricardo, Ng, Terry L., Alzahrani, Mashari Jemaan, Raphael, Jacques, Blanchette, Phillip, Black, Morgan, Stober, Carol, Pond, Gregory R., Cella, David, Vandermeer, Lisa, Ibrahim, Mohammed, Clemons, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453132/
https://www.ncbi.nlm.nih.gov/pubmed/37623016
http://dx.doi.org/10.3390/curroncol30080535

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453132/
https://www.ncbi.nlm.nih.gov/pubmed/37623016
http://dx.doi.org/10.3390/curroncol30080535

Ejemplares similares